Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Terminated 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 4Breast 4Thoracic 3Lymphoid 2Head & Neck 2Other solid neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 1Patient Preference 1Inflammatory Breast Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1

Interventions

Trastuzumab 692Paclitaxel 678Cyclophosphamide 634Docetaxel 553Capecitabine 467Letrozole 407Carboplatin 392Fulvestrant 377Doxorubicin 330Tamoxifen 288pembrolizumab 270Anastrozole 252Epirubicin 249exemestane 238pertuzumab 226Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Injections, Subcutaneous × Breast × Clear all
NCT05296798 2026-04-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Hoffmann-La Roche

Phase 3 Active not recruiting
922 enrolled
Breast

Breast Neoplasms

NCT05415215 2026-02-10

ProHer

Hoffmann-La Roche

Phase 3 Completed
346 enrolled 20 charts
Breast

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT07036185 2025-06-25

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Shanghai Bao Pharmaceuticals Co., Ltd.

Phase 1 Not yet recruiting
66 enrolled
BreastGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04675827 2024-12-04

Decrescendo

Jules Bordet Institute

Phase 2 Terminated
139 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡